A quiet neighborhood pharmacy in Fort Worth has turned into a viral whistleblower after posting a price comparison that lands like a gut punch to the taxpayer. The shop says it can buy a common cancer pill for about $7 a month and sell it to cash customers for $17, while a recent 30-day fill of the same drug was billed to Medicare at roughly $2,400. The owners argue that the gap is not a glitch but the predictable outcome of the payment rules and middlemen that control where and how prescriptions get filled. Locals and nearby pharmacists have been punching numbers into the store’s online price tool to check the math, and the dust-up has reignited a national fight over how pharmacy benefit managers shape what patients and taxpayers actually pay.
Viral post lays out the math
Speaking with The Dallas Express, co-owner Brad Hart said Forest Park Pharmacy buys the medication for around $7, then tacks on a modest markup plus a $10 dispensing fee to land at a $17 cash price for a 30-day supply. Yet, he said, Medicare Part D reimbursements that the pharmacy has seen for the same drug and quantity hover near $2,400. “We just buy the medication from wholesalers ... after all of our additions $17 is the total price, but because of all the crazy reasons with insurance, Medicare is paying that $2,400 price,” Hart told the outlet. After the store posted the comparison online, independent pharmacists around the country amplified it, pointing to similar spreads on their own shelves.
How PBMs set the price and why it can spike
Pharmacy benefit managers, intermediaries that negotiate rebates, assemble pharmacy networks and process prescription claims, now control a hefty share of the prescription market and, with it, much of the pricing power at the counter. Drug Channels reports that the three largest PBMs handled roughly 80% of equivalent prescription claims in recent industry data. At the same time, federal Medicare Part D rules often tie negotiated drug prices to benchmarks such as the average wholesale price (AWP), a figure that can sit far above what pharmacies actually pay to acquire the medications, according to the Federal Register. When those formulas collide with opaque contracts, a $7 pill can suddenly look like a four-figure claim.
Studies and regulators have flagged the same pattern
Researchers and federal watchdogs say what is playing out in Fort Worth fits a broader pattern. A JAMA Network analysis documented extreme markups on certain generic drugs, including cases in which pharmacies paid only a few dollars for a medication that was then reimbursed in the thousands at the point of sale. In January 2025, an interim staff report from the Federal Trade Commission similarly found that vertically integrated PBMs had marked up dozens of specialty generics by hundreds or even thousands of percent, generating billions in additional revenue for PBMs and their affiliated pharmacies and triggering closer regulatory scrutiny.
Where the Fort Worth pharmacy fits in
Forest Park Pharmacy operates on a cash, cost-plus model and publishes a price checker that shows its cash prices alongside insured prices, according to the store’s website. The owners say steering clear of insurance contracts lets them post straightforward prices and sidestep contractual clauses that can prevent independent pharmacies from undercutting plan rates, a strategy detailed in a local profile by the Fort Worth Report. Hart contends there are “hundreds” of medications with similar gaps between acquisition cost and what insurance ends up paying, and he urges customers to check cash prices before assuming their plan is the cheapest route.
What comes next
Regulators and lawmakers are already circling. The FTC and other federal officials have held hearings and issued staff reports that put PBM business practices under a microscope, while national outlets have chronicled the agency’s findings. Proposals now on the table include requiring more transparency in PBM contracts, limiting how much plans can steer patients to PBM-owned specialty pharmacies, and reworking how Medicare Part D calculates reimbursements. None of that will be quick, given the complexity and age of the existing contracts and formulas.
In the meantime, independent pharmacies are leaning on public price tools and viral social posts to drag the debate out of policy documents and into everyday conversation. For patients and taxpayers, the Fort Worth flare-up is a blunt reminder that list prices, acquisition costs and what Medicare ultimately pays can be miles apart, and that whoever controls the contract usually decides which number wins.
